Generation of Engineered Human Myocardium in a Multi-well Format.


Journal

STAR protocols
ISSN: 2666-1667
Titre abrégé: STAR Protoc
Pays: United States
ID NLM: 101769501

Informations de publication

Date de publication:
19 06 2020
Historique:
entrez: 28 10 2020
pubmed: 29 10 2020
medline: 29 10 2020
Statut: epublish

Résumé

This protocol describes a robust method for the generation of engineered human myocardium (EHM) from pluripotent stem cells (PSCs) in a multi-well plate under defined, serum-free conditions. By parallel culture of up to 48 EHM in one plate, contractile heart muscle can be obtained to serve numerous applications, including drug screening and disease modelling. This protocol has been successfully applied to human embryonic stem (HES) cell- and induced PSC-derived cardiomyocytes, subtype-specific, i.e., atrial and ventricular, and commercially available cardiomyocyte preparations. For complete details on the use and execution of this protocol, please refer to Tiburcy et al. (2017).

Identifiants

pubmed: 33111083
doi: 10.1016/j.xpro.2020.100032
pii: S2666-1667(20)30019-8
pmc: PMC7580201
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

100032

Informations de copyright

© 2020 The Author(s).

Déclaration de conflit d'intérêts

M.T., T.M., and W.H.Z. are listed as inventors of patents related to the EHM technology. M.T., T.M., and W.H.Z. are scientific advisors to myriamed GmbH. W.H.Z. is founder and shareholder of myriamed GmbH and Repairon GmbH.

Références

Curr Protoc Cell Biol. 2012 Jun;Chapter 23:Unit23.8
pubmed: 23129117
Cell Stem Cell. 2011 Feb 4;8(2):228-40
pubmed: 21295278
J Am Coll Cardiol. 2017 Aug 22;70(8):975-991
pubmed: 28818208
Prog Biophys Mol Biol. 2019 Jul;144:51-60
pubmed: 30553553
Stem Cell Res. 2015 Sep;15(2):365-75
pubmed: 26318718
JCI Insight. 2018 Jun 21;3(12):
pubmed: 29925689
Methods Mol Biol. 2014;1181:167-76
pubmed: 25070336
Circulation. 2017 May 9;135(19):1832-1847
pubmed: 28167635
Circ Res. 2015 Sep 25;117(8):720-30
pubmed: 26291556

Auteurs

Malte Tiburcy (M)

Institute of Pharmacology and Toxicology, University Medical Center Göttingen, Göttingen, Germany.
DZHK (German Center for Cardiovascular Research), Partner Site Göttingen, Göttingen, Germany.

Tim Meyer (T)

Institute of Pharmacology and Toxicology, University Medical Center Göttingen, Göttingen, Germany.
DZHK (German Center for Cardiovascular Research), Partner Site Göttingen, Göttingen, Germany.

Norman Y Liaw (NY)

Institute of Pharmacology and Toxicology, University Medical Center Göttingen, Göttingen, Germany.
DZHK (German Center for Cardiovascular Research), Partner Site Göttingen, Göttingen, Germany.

Wolfram-Hubertus Zimmermann (WH)

Institute of Pharmacology and Toxicology, University Medical Center Göttingen, Göttingen, Germany.
DZHK (German Center for Cardiovascular Research), Partner Site Göttingen, Göttingen, Germany.
Cluster of Excellence "Multiscale Bioimaging: from Molecular Machines to Networks of Excitable Cells" (MBExC), University of Göttingen, Göttingen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH